Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 20/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 18/20 | 1.00 |
| ▸ | SGK1 | O00141 | 1/20 | 0.90 |
| ▸ | AKT1 | P31749 | 1/20 | 0.90 |
| ▸ | GSK3B | P49841 | 1/20 | 0.90 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.90 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.90 |
| ▸ | DMPK | Q09013 | 1/20 | 0.90 |
| ▸ | MYLK | Q15746 | 1/20 | 0.90 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.90 |
| ▸ | PRKACA | P17612 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29431307 | 1.00 | ROCK1 (1.00) | ROCK1ROCK2SGK1AKT1GSK3B | |
| Hydrochloric Acid SCHEMBL29633094 | 0.99 | ROCK1 (0.98) | ROCK1ROCK2SGK1AKT1GSK3B | |
| Hydrochloric Acid SCHEMBL17836965 | 0.99 | ROCK1 (0.98) | ROCK1ROCK2SGK1AKT1GSK3B | |
| SCHEMBL2551860 | 0.95 | ROCK1 (1.00) | ROCK1ROCK2SGK1AKT1GSK3B | |
| SCHEMBL23352214 | 0.92 | ROCK1 (0.85) | ROCK1ROCK2SGK1AKT1GSK3B | |
| SCHEMBL2559909 | 0.88 | ROCK1 (1.00) | ROCK1ROCK2SGK1AKT1GSK3B | |
| SCHEMBL2560469 | 0.88 | ROCK2 (1.00) | ROCK1ROCK2SGK1AKT1GSK3B | |
| SCHEMBL2554347 | 0.88 | ROCK1 (1.00) | ROCK1ROCK2SGK1AKT1GSK3B | |
| SCHEMBL2555028 | 0.88 | ROCK1 (1.00) | ROCK1ROCK2SGK1AKT1GSK3B | |
| SCHEMBL2557781 | 0.87 | ROCK1 (1.00) | ROCK1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 655 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746855-A1 | FORMULATIONS AND USES OF ROCK2 INHIBITORS FOR ALS | Graviton Bioscience BV (NL) | 2026-05-27 | — | — | EP | claimed |
| CN-122094667-A | Formulations and uses of ROCK2 inhibitors for ALS | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026103625-A1 | METHOD FOR CONSTRUCTING THYMUS ORGANOID AND USE THEREOF | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | 2026-05-21 | — | — | WO | claimed |
| EP-4744663-A2 | SKIN COMPOSITION | Eaderm Co., Ltd. (JP) | 2026-05-20 | — | — | EP | claimed |
| CN-120866196-B | Serum-free embryo cutting biopsy culture solution and application thereof | 中国农业大学 | 2026-05-15 | — | — | CN | claimed |
| WO-2026090172-A1 | CELL CULTURE SYSTEMS COMPRISING MICROPATTERNED ARRAYS AND METHODS OF USE | ALTIS BIOSYSTEMS, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4728051-A1 | STANDARDISING PLURIPOTENT STEM CELLS | United Kingdom Research and Innovation (GB) | 2026-04-22 | — | — | EP | claimed |
| US-20260076969-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-03-19 | — | — | US | claimed |
| EP-4709477-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF MICROVASCULATURE DYSFUNCTION AND RELATED DISEASES | The Texas A&M University System (US) | 2026-03-18 | — | — | EP | claimed |
| EP-3843845-B1 | INHIBITION OF PROTEIN KINASES TO TREAT FRIEDREICH ATAXIA | UNIV MASSACHUSETTS (US) | 2026-03-11 | — | — | EP | claimed |
| EP-3946268-A1 | INHALED STATINS AS BRONCHODILATORS TO IMPROVE LUNG FUNCTION IN RESPIRATORY DISEASES | The Regents of The University of California (US) | 2022-02-09 | — | — | EP | claimed |
| US-20210340498-A1 | MEDIUM FOR DIRECT DIFFERENTIATION OF PLURIPOTENT STEM CELL-DERIVED MESENCHYMAL STEM CELL, METHOD FOR PREPARING MESENCHYMAL STEM CELL BY USING SAME, AND MESENCHYMAL STEM CELL PREPARED THEREBY | CHA BIOTECH CO., LTD. (KR) | 2021-11-04 | — | — | US | claimed |
| US-20210292766-A1 | Inhibition of Protein Kinases to Treat Friedreich Ataxia | UNIVERSITY OF MASSACHUSETTS | 2021-09-23 | — | — | US | claimed |
| EP-3848455-A1 | MEDIUM FOR DIRECT DIFFERENTIATION OF PLURIPOTENT STEM CELL-DERIVED MESENCHYMAL STEM CELL, METHOD FOR PREPARING MESENCHYMAL STEM CELL BY USING SAME, AND MESENCHYMAL STEM CELL PREPARED THEREBY | CHA Biotech Co., Ltd. (KR) | 2021-07-14 | — | — | EP | claimed |
| EP-3843845-A1 | INHIBITION OF PROTEIN KINASES TO TREAT FRIEDREICH ATAXIA | University Of Massachusetts (US) | 2021-07-07 | — | — | EP | claimed |
| CN-112996903-A | Culture medium for directly differentiating pluripotent stem cell-derived mesenchymal stem cells, method for preparing mesenchymal stem cells by using culture medium and mesenchymal stem cells prepared by using culture medium | 车比奥泰有限公司 | 2021-06-18 | — | — | CN | claimed |
| WO-2020047229-A1 | INHIBITION OF PROTEIN KINASES TO TREAT FRIEDREICH ATAXIA | UNIVERSITY OF MASSACHUSETTS (US) | 2020-03-05 | — | — | WO | claimed |
| US-20160230142-A1 | CORNEAL STROMAL KERATOCYTE CULTURE | SINGAPORE HEALTH SERVICES PTE LTD (SG) | 2016-08-11 | — | — | US | claimed |
| EP-3047018-A1 | CORNEAL STROMAL KERATOCYTE CULTURE | Singapore Health Services Pte Ltd (SG) | 2016-07-27 | — | — | EP | claimed |
| WO-2015041606-A1 | CORNEAL STROMAL KERATOCYTE CULTURE | SINGAPORE HEALTH SERVICES PTE LTD (SG) | 2015-03-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076969-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | ATP5ME, MT-ATP6, ATP5MK | ROCK1 238/4885ROCK2 341/4885SGK1 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.